Follitropin alfa

Drug Profile

Follitropin alfa

Alternative Names: Follitropin-alpha; GONAL-f; GONAL-f RFF Redi-ject; Recombinant human follicle-stimulating hormone - Merck Serono; recombinant human follicle-stimulating hormone - Serono; rh-FSH; rhFSH - Merck Serono; rhFSH - Serono; SJ-0021

Latest Information Update: 27 Mar 2017

Price : $50

At a glance

  • Originator Merck Serono
  • Developer EMD Serono; Merck Serono; Nippon Shinyaku
  • Class Follicle stimulating hormones; Infertility therapies; Peptide fragments; Pituitary gonadotropins; Recombinant proteins
  • Mechanism of Action Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Male infertility
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Female infertility; Male infertility

Most Recent Events

  • 01 Jul 2015 Follitropin alfa licensed to Nippon Shinyaku in Japan for Male infertility and Female infertility
  • 16 Jan 2014 Phase-III clinical trials in Female infertility (combination therapy) in Finland, Germany, Hungary, Latvia and the United Kingdom (SC)
  • 01 Jan 2014 Phase-III clinical trials in Female infertility (Combination therapy) in Sweden, Poland, Spain, Denmark, Netherlands, Estonia, Belgium, Czech Republic (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top